US approval for Sanofi’s late-onset Pompe disease med Nexviazyme
The enzyme replacement therapy is designed to target the key mannose-6-phosphate receptor pathway
Read More
Tag: Pompe disease
Amicus’ Pompe disease therapy joins early access scheme
The MHRA has issued an EAMS scientific opinion opening the door to use of cipaglucosidase alfa with miglustat in eligible patients with Pompe disease
Read More
MHRA deems Sanofi’s avalglucosidase alfa ‘promising’ for Pompe disease
New therapy granted a Promising Innovative Medicine designation by UK agency
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
